AU771188B2 - Use of protein conformation for the protection and release of chemical compounds - Google Patents

Description

WO 00/52078 PCT/US00/05693 USE OF PROTEIN CONFORMATION FOR THE PROTECTION AND RELEASE OF CHEMICAL COMPOUNDS FIELD OF THE INVENTION The present invention is directed to the preparation of synthetic amino acid polymers and is directed to the use of these polymers to protect chemical compounds, especially drug substances, from degradation, and to release the compounds under specific conditions.

BACKGROUND OF THE INVENTION Under physiologic conditions, proteins (polymer chains of peptide-linked amino acids) normally do not exist as extended linear polymer chains. A combination of molecular forces, including hydrogen bonding, hydrophilic and hydrophobic interactions, promote thermodynamically more stable secondary structures that can be highly organized (helices, beta pleated sheets, etc.). These structures can then combine to form higher order structures with critical biological functions. Natural proteins are peptide-linked polymers containing 20 different amino acids, each with a different side-chain. The details of the folding into higher order structures are dependent on the type, frequency and primary sequence of the amino acids in the protein. Since each position in the polymer chain can be occupied by 20 different amino acids, the thermodynamic rules that describe the details of protein folding are complex. For example, we are currently unable to design a synthetic protein with a substrate-specific enzymatic site that is predicted by the primary amino acid sequence. More complete discussions of the structure and function of proteins are found in Dickerson et al. "The Structure and Action of Proteins" Harper and Row, New York, 1970 and Lehninger "Biochemistry" Worth, New York, 1970, pp. 109-146.

However, some basic rules of protein folding have been discovered. In general, the side chains of the 20 L-amino acids commonly found in natural proteins can be placed in two categories, hydrophobic/non-polar and hydrophilic/polar, each playing separate roles in protein conformation. In the standard "oil drop" model for protein folding, the amino acids with more hydrophobic side chains (Val, Leu, Phe, Met, Ilu) are sequestered to the inside of the protein structure, away from the WO 00/52078 PCT/US00/05693 aqueous environment. Frequently, these hydrophobic side chains form "pockets" that bind molecules of biological significance. On the other hand, hydrophilic amino acids Lys, Arg, Asp, Glu) are most frequently distributed on the outer surface of natural proteins, providing overall protein solubility and establishing a superstructure for the internalized hydrophobic domains.

A highly preferred conformation found in many natural proteins is the 3.613 alpha-helix. This right-handed helix contains 3.6 amino acids per turn and is stabilized by hydrogen bonding (about 3 kcal/mol) involving the amide hydrogen and a carbonyl oxygen, separated by 13 atoms along the backbone of the polymer chain. Since the amino acid side chains in the alpha-helix point away from and perpendicular to the helix axis, any of the amino acids (except Pro) can participate in the helix. Other structures can also appear in higher order protein conformations, including the 310 helix, and the important left-handed, three residue helix found in collagen and pleated sheets.

Other amino acids can also be used with predictable results in the preparation of synthetic proteins. Tyrosine (Tyr) is frequently found internalized, with its 4hydroxy hydrogen, hydrogen-bonded to another amino acid or potential ligand/enzyme substrate. Thus, Tyr can be utilized to produce hydrophobic pockets with a potential for hydrogen bonding. Proline (Pro) has been found to be sufficient, but not always necessary, for a sharp turn in the peptide chain, allowing for cooperative interactions of different sections of the same polymer. At higher polymer concentrations, Pro can also disrupt helical structure, producing a "less organized" protein. Cystine can be utilized to stabilize higher order structures by linking polymer chains through high energy (about 50 kcal/mol) disulfide bonds.

Some amino acids do not have distinct hydrophobic or hydrophiiic character and provide a "place-keeping" function or contribute more subtle effects on the overall protein structure.

Some work on synthetic polypeptides has proceeded with the goal of producing textile products with desirable properties, but the technology has been largely too expensive to compete with natural products, and with other synthetic polymers. In the pharmaceutical industry, work on synthetic polypeptides has WO 00/52078 PCT/US00/05693 focused* again on specific amino acid sequences having intrinsic hormonal or drug activities. A more complete discussion of the use of synthetic polymers for textiles and pharmaceuticals is provided by Block in "Polymer: Monographs" Gordon and Breach, Vol 9, 1983. An historical perspective is provided by Watson "Molecular Biology of the Cell" W.A. Benjamin, Inc., New York, 1970.

It was not realized, prior to the present invention, that block polymers, comprised of a limited sub-set of amino acids, would exhibit intrinsic conformational structures that could be predicted, based on an analysis of statistical distributions and ratios of the amino acids in the polymer. Moreover, it was also not realized that these synthetic proteins would have utility in protecting and releasing sensitive chemical compounds.

Thus, the present invention describes a use of a limited but sufficient sub-set of amino acids, to produce prototype synthetic proteins that reproduce certain conformational aspects of natural proteins. The present invention describes the use and combination of only seven amino acids, each with a specific function in the resulting synthetic polypeptide: Glutamic Acid (Glu), Lysine (Lys), Phenylalanine (Phe), Proline (Pro), Tryptophan (Trp), Tyrosine (Tyr) and Cysteine (Cys). Cys is used herein as the disulfide Bis-dimer (CysS-SCys), referred to as cystine by convention. Block polymers of this amino acid subset are used to produce synthetic proteins with predictable conformations and utility. The ability of these synthetic polypeptides to organize into higher order structures, and in some embodiments, to form hydrophobic domains, are used in the present invention to protect sensitive compounds from chemical oxidative) and enzymatic degradation and provide for the engineered release of these compounds under specific conditions.

SUMMARY OF THE INVENTION The subject of this invention is the utilization of the ability of amino acid polymers (polypeptides) to form higher order structures. These structures can bind to and protect chemical entities drugs) from chemical and enzymatic degradation and provide a mechanism for controlled release of such entities.

Synthetic polypeptides are described that are composed of carefully selected WO 00/52078 PCT/US00/05693 combinations and ratios of amino acids, including a hydrophilic/polar component (like Glu or Lys), a hydrophobic component (like Tyr, Phe or Benzyl Glu), and are designed to promote the formation of internalized domains, to accommodate chemical entities like drugs.

In one embodiment, the method relates to the protection of a chemical compound from degradation comprising combining the chemical compound with a synthetic protein which may be a homo-polymer, containing for example Glu or Lys, or may be a co-polymer with an amino acid having hydrophobic character, contributes a hydrogen bonding capacity, or stabilizes higher order structures.

In another embodiment, the invention relates to cell culture media comprising a synthetic polypeptide containing Gin that is co-polymerized with an amino acid, like Glu. The polymer provides a chemically stable nutritional source of Gin in the culture. A related embodiment utilizes a Gin containing synthetic protein as a nutritional source of Gin in humans.

In another embodiment, the invention relates to a pharmaceutical composition comprising an active ingredient that has been combined with a synthetic amino acid polymer. The synthetic protein may be a homo-polymer of Glu or Lys, for example, or may be a co-polymer containing Glu or Lys and Tyr, Phe or Benzyl Glu. In specific related embodiments, the active ingredient of such pharmaceutical compositions is L-DOPA, aspirin, hydrocortisone, or estrogen. The protein/active ingredient combination may also be combined with other pharmaceutically acceptable excipients to aid in tablet formation and properties, for example.

In yet another embodiment, the invention relates to a method of controlling the release of a chemical compound based on response to changes in pH. This embodiment is comprised of manipulating the higher order structure of a synthetic protein by choice of amino acid composition and combining said chemical compound with the protein.

In another embodiment, the invention relates to the release of chemical compounds by regulating the rate of proteolytic digestion through the manipulation of higher order structures of a synthetic protein by choice of amino acid composition, and combining said chemical compounds with the protein.

WO 00/52078 PCT/US00/05693 In another embodiment, the invention relates to the release of chemical compounds by regulating thermal diffusion of said compounds from a synthetic protein. Regulation of diffusion rate occurs by manipulating the higher order structure of the synthetic protein, by choice of amino acid composition, and combining said chemical with the protein.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

Unless otherwise indicated, a parameter that is qualified by "about" may vary 10 from the stated value. That is, "about 50 means 45-55 °C.

Further, unless otherwise indicated, all amino acids are in the L-form.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS A number of general methods could be used in the present synthesis of synthetic polypeptides, but the most suited is the Fuchs-Farthing approach. In this method, the parent amino acid is condensed with Phosgene under anhydrous conditions to form the N-chlorocarbonyl intermediate. Depending on the specific amino acid used, the R group functionality may require protection to block involvement in the reaction. The intermediate loses HC1 as it cyclizes to form the N-carboxyanhydride (NCA). Currently, it is more convenient and safe to substitute triphosgene [Bis(trichloromethyl)carbonate] for neurotoxic Phosgene (gas) since triphosgene is a rystalline solid that is easily weighed and added to the NCA reaction. Thus, triphosgene is a preferred reagent for amino acid NCA formation.

Additional advantages to the Fuchs-Farthing chemistry are that the NCA's are generally easy to purify in crystalline form, negligible racemization occurs at the alpha carbon and the polymerization reaction yields only the protein polymer and non-toxic carbon dioxide.

WO 00/52078 PCT/US00/05693 The polymerization reaction normally contains an amino acid NCA (for homopolymers) or mixture of NCA's, for the synthesis of co- or heteropolymers, together with a polymerization initiator, all dissolved in a compatible solvent system. Highly preferred for the polymerization is a non-protic organic solvent that has high solubility for the NCA and the polymer. The preferred solvents include ethyl acetate, THF, benzene, dichloromethane, DMF and dioxane. Most preferred solvents include THF dioxane and DMF. In the case of co-polymer synthesis, solubility of the polymer in the polymerization solvent is important, since early precipitates of polymer, prior to complete use of all the NCA monomers, may favor the appearance of one amino acid over another, in the first precipitates.

The initiator of the polymerization reaction can be water, a base (organic or inorganic) or a preformed amino acid polymer. In theory, the average number of amino acid residues in the final polymer product is a direct result of the molar ratio of the monomer NCA's to the initiator. Since initiation may not behave ideally, through, for example, partitioning of the initiator into non-polymerizing compartments in the reaction, care must also be taken to use an initiator that is highly soluble in the reaction solvent. Most preferably, a tertiary amine, like triethyamine or tert-butylamine is used, since primary and secondary amines may stay covalently attached to the polymer, forming stable end-labeled polymer products.

The preferred average number of residues in the polymer chains is between 5 and 400. For polymers like PGlu and PLys, where helical structure may be desired, an average N between 10 and 400 is most preferred.

Of particular importance to the present invention are the claimed mechanisms of protection and release of chemical compounds from synthetic protein polymers.

A useful embodiment of the invention is the formulation of tablets or liquids intended for oral delivery of an active drug substance. Standard formulations of drugs may have limited shelf-life from oxidation) or be inactivated by the acidic conditions of the stomach. In this case, a drug delivery mechanism that circumvents the stomach would be desirable. Alternatively, rapid release of a drug substance in the stomach may be preferred.

WO 00/52078 PCT/US00/05693 In order to address these desired applications, chemical compounds may be formulated as defined herein. "Macroformulation": blending of a powdered chemical compound and a powdered synthetic polypeptide prior to formulation and tableting. "Microformulation": incorporation of a chemical compound into a synthetic polypeptide, for example by inclusion into hydrophobic pockets, prior to formulation and tableting. "Covalent formulation": incorporation of a chemical compound by peptide linkages into a synthetic polypeptide prior to formulation and tableting.

A focus of the present invention makes use of a dramatic effect of pH on secondary and tertiary structures of synthetic protein polymers containing an ionizable R group Glu, Asp, Lys, Arg). At a pH around the pKA, the ionizable portion makes a transition from uncharged to highly charged. As a result of all the closely spaced repulsive charges higher order polymeric structures, like alpha helices, are rapidly converted to "random coils." Random coils are highly flexible and dynamic; this form promotes drug release and enhanced proteolytic cleavage by digestive enzymes.

For example, a drug can be blended in powder form with polyglutamic acid (PGlu) and tableted by direct compression. Stability of the drug in this "macroformulated" tablet is achieved by internalization of the drug into the compressed matrix, an environment that is nearly anhydrous and low in oxygen. The presence of water and oxygen is known to be detrimental to drug stability. After ingestion, the external surface of the tablet is exposed to the low pH of the stomach (about pH= Since the pKA of the gamma carboxyl group of Glu is 4.25, the carboxyl groups remain in the -COOH form, the tablet remains compact, digestion of thepolymer is slow and release of the co-formulated drug is slow.

However, upon passing the pyloric valve, the pH of the intestinal contents increases to about 6.5 and the carboxyl groups become de-protonated and highly charged. The closely spaced, highly charged carboxyl groups repel each other strongly enough to overcome intrachain bonds hydrogen bonds) responsible for higher order structure of the PGlu. The drug then diffuses from the loose, random coils of the polymer. The enhanced digestability of the random coil structure also WO 00/52078 PCT/US00/05693 aids drug release. Through this mechanism, the drug is released preferentially in the small intestine.

Similarly, a drug intended for oral delivery is "macro-formulated" with polymeric lysine (PLys) by blending and tableting by direct compression). In this case, the omega amino group of Lys has a pKA of about 10.0. Once entering the stomach, the omega amino group becomes fully protonated and highly charged.

The closely spaced amino groups repel each other, releasing the drug substance by diffusion and enhanced digestability of the random coil structure.

A further enhancement of drug stability and controlled release properties, especially in the digestive system, can be realized by incorporation of a hydrophobic amino acid, like Phe, to form a synthetic co-polymer. In one embodiment, a synthetic co-polymer containing Glu and Phe, in a preferred ratio is, "macroformulated" with a hydrophobic drug substance. Stability of the drug in the compressed tablet is again enhanced by sequestration from water and oxygen.

Release of the drug in stomach is slow. However, once in the small intestine, the PGlu/Phe becomes less organized due to pH/charge effects and there is an initial release of drug substance accompanied by re-partitioning of the drug into hydrophobic domains in the polymer. Finally, terminal digestive proteolysis releases the entire store of drug.

Similarly, PLys/Phe can be used for release of a drug substance in the stomach, except that drug release and digestion of the polymer are enhanced in the stomach, and the drug release profile is blunted by successive re-partitioning of the drug into the hydrophobic domain of the polymer. Finally, digestive proteolysis destroys even the hydrophobic pockets, releasing all the drug.

A further enhancement of drug stability is accomplished by microfoilaMulation involving inclusion of the drug, into the internal matrix of the synthetic protein prior to tableting and oral administration. For example, a hydrophobic drug substance is combined in solution with a co-polymer of glutamic acid and phenylalanine (PGlu/Phe) at a pH that favors the random coil form of the polymer (pH The solution is slowly acidified to promote the formation of higher order structures in the polymer, with attendant formation of internalized hydrophobic domains -8- WO 00/52078 PCT/US00/05693 containing the "dissolved" hydrophobic drug substance. The PGlu/Phe Drug Substance combination precipitates at lower pH; precipitation can be enhanced by the addition of an organic solvent like acetone. The vacuum or freeze dried product is especially stable since the drug substance is partitioned into anhydrous, hydrophobic domains inside the protein structure.

A similar process of drug inclusion applies to PLys/Phe except that higher order structures, like alpha helices, occur above pH 10 for this polymer. In this case, the polymer/drug combination is adjusted to pH 11 in solution and freeze dried. Again, the product is especially stable due to partitioning of the drug into hydrophobic domains inside the protein. The polymer/drug complexes can be formulated with other excipients that may facilitate tableting.

Certain drug substances, like DOPA and glutamine (Gln), are also amino acids and are therefore amenable to co-polymerization into the primary polypeptide chain, affording drug protection as described above and an additional control of drug release, requiring proteolytic digestion. An embodiment demonstrating the advantage of this covalent formulation is the protection of Gin from degradation.

Gln is an essential amino acid for most mammalian cells and is therefore an important nutritional component, for example in cell culture. However, monomeric Gin is chemically unstable, degrading to ammonia and pyrrolidonecarboxylic acid, under physiologic conditions. Gin is chemically stabilized as a co-polymer with Glu by incorporation into the structure of the polymer. As an oral nutritional supplement in humans, Gin release is regulated by normal proteolytic digestion of the polymer. Gin is released for metabolic use by cultured cells by slow extracellular hydrolysis of the synthetic protein in the culture media or by pinocytotic mechanisms in which the synthetic protein is internalized by the cultured cells and digested by lysozomes to become a metabolic source of Gin.

Other hydrophobic amino acids find special use when co-polymerized with a hydrophilic component like Glu or Lys. For example, Tyrosine (Tyr) is moderately hydrophobic and can also hydrogen bond with potential drug substances via its 4- OH group. Tryptophan (Trp) is less hydrophobic than Phe and provides internalized hydrophobic domains that permit relatively enhanced diffusion of drug WO 00/52078 PCT/US00/05693 substances under physiologic conditions. Trp-NCA synthesis is also facilitated since the secondary nitrogen does not need protected.

Proline (Pro) is used in the present invention to provide obligatory turns in structures like helices, providing for enhanced intrachain interactions and promoting the formation of more globular synthetic proteins, when preferred. At higher levels, Pro destabilizes higher order protein structures since it cannot participate in helical structures and can be used in a co-polymer to enhance diffusion of a drug substance from hydrophobic domains internalized in a synthetic protein. D-amino acids also inhibit formation of helical structures of L-amino acids but are less desirable due to their possible unwanted metabolic effects as an unnatural amino acid.

Cystine is used in the present invention to stabilize higher order structures via intra- and inter-chain disulfide linkages. This is accomplished in the present invention using the bifunctional Bis-disulfide NCA, since the disulfide linkage serves as its own thiol protecting group.

An additional object of the present invention is the synthesis of a synthetic protein for use in the preparation of a synthetic serum. In this capacity, a globular protein that is metabolically stable, non-immunogenic and non-allergenic is highly desired. As an artificial serum component, a heteropolymer containing Glu, Pro, Tyr, and Cys has been prepared with the desired properties.

The synthetic polypeptides in the current application are also referred to as synthetic proteins or synthetic amino acid polymers. Polypeptides of the invention have two or more amino acids linked by a peptide bond. In a preferred embodiment, polypeptides have five or more peptide linked amino acids.

The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.

Example 1: Preparation of Microcrystalline L-Glutamic Acid L-Glutamic acid (200 gm) is dissolved in 2.5 L hot water (T >95 The hot solution is added slowly to 2.5 L of rapidly stirred, cold (T 10 C) acetone to WO 00/52078 PCT/US00/05693 form a thick slurry. After cooling, the precipitated solid is separated by filtration, washed with 200 ml of acetone and the filter cake compressed to remove excess solvent. The white filter cake is dried in vacuo at 80 C for 4 hours and is suitable for use in Example 2. Yield: 189 gm (94 "Microcrystalline" means that the crystalline nature is not obvious by macroscopic inspection; the resulting L- Glutamic acid is amorphous.

Example 2: Synthesis of Glutamic N-Carboxyanhydride (Glu-NCA) Microcrystalline, dry L-Glutamic Acid (73.6 gm, 0.5 mol) from Example 1 is suspended in 2.0 L of anhydrous THF containing triphosgene (98 gm, 1 Eq.) and heated with stirring to 50 °C for 4 hours or until the reaction is homogeneous. The reaction is then heated to a gentle reflux for about 1 hour, using a condenser protected with a drying tube. "About 1 hour" means 1 hour 20 min. The solution is then decanted or filtered from any remaining solids and evaporated under oil vacuum using a water bath less than 40 until a precipitate forms or until a thick oil remains, with no additional solvent evaporation. The product is dissolved in 360 ml of dry ethyl acetate, any insoluble material gm) is filtered off, and the crude product is precipitated by the rapid addition of 360 ml of hexanes with active stirring. After 20 min., an additional 200 ml of hexanes is added to fully precipitate the crude Glu-NCA. The precipitate is collected by filtration under a dry carbon dioxide curtain, wash the filter cake with hexanes (100 ml) and compact under pressure to remove excess solvent. In order to purify the crude Glu-NCA, the hexane-damp filter cake is dissolved in a combination of 350 ml anhydrous THF and 350 ml of anhydrous ethyl acetate. Any insoluble material is filtered off and is precipitated with rapid addition of 700 ml of hexanes with stirring. Once precipitation has commenced, an additional 350 ml hexanes is added to complete the precipitation. After 30 min, the precipitate is isolated by filtration under a dry carbon dioxide curtain. The product is compacted with pressure to remove excess solvent, and it is then washed with hexanes (100 ml) and dried in vacuo (T 30 C).

The product is stable when stored under dry carbon dioxide, in the cold (temperature is less than about 10 where "about 10 means 5 -11- WO 00/52078 PCT/US00/05693 Example 3: Synthesis of Polymeric Glutamic Acid (PGlu) The dry Glu-NCA product (17.3 gm, 100 mmol) of Example 2 is dissolved in anhydrous THF (86 ml) and polymerization is initiated by the addition of 86 ml of anhydrous ethyl acetate containing 0.1 gm triethylamine. The reaction is warmed to reflux for 15 min then allowed to cool and react at 25 °C for 24 hours with continuous stirring. The precipitate is isolated by filtration, washed with anhydrous diethyl ether and dried in vacuo at 60 °C for 2 hours, to yield a white powder.

Yield: 10.2 gm Example 4: Synthesis of Polymeric Lysine (PLys) Polymeric L-Lysine is prepared as previously described (Sela et. al., Biopolymers 1,517, 1963). The dry polymer is converted to the alpha helical form, and contaminant bromine is removed by dissolving in water as a 10 solution and titrating the pH to 12 by the addition on 1.0 N NaOH. The spontaneous precipitate is further precipitated by the addition of acetone and collected by filtration and vacuum dried to obtain a white powder. Yield: 78 from the starting polymeric Lysine. The helical form is confirmed by measuring the optical rotation [alpha] D of the pH 12 solution (minimal negative value of -40 degrees optical rotation, compared to -130 degrees optical rotation for the random coil).

Example 5: Synthesis of Glutamic Acid/Phenylalanine Co-Polymer (PGly/Phe) The conditions of Example 3 are repeated except that Glu-NCA (12.46 gm, 72 mmol) and Phe-NCA (5.35 gm, 28 mmol) are co-dissolved in the THF. Crude Phe-NCA is prepared by the method of Poche (Tet. Letters 29:5859-5862, 1988).

However, the crude Phe-NCA is further purified prior to polymerization by dissolving 50 gm in a mixture of 100 ml of THF and 100 ml of ethyl acetate followed by precipitation with 600 ml of hexanes. The fluffy, white product is isolated by filtration, washed with hexanes and dried in vacuo to yield 36 gm WO 00/52078 PCT/US00/05693 Example 6: Synthesis of Lysine/Phenylalanine Co-Polymer (PLys/Phe) Example 4 is repeated except that Phe-NCA is included in the polymerization to for the co-polymer in a final Lys/Phe ratio of 3.6. The polymer is converted to the helical form as described in Example 4.

Example 7: Synthesis of Glutamic Acid/Glutamine Co-Polymer (PGlu/Gln) The polymer of Example 3 is converted to the Glu/Gln co-polymer.

Polymeric glutamic acid (20 gm) is suspended in 100 ml of water, with stirring, and heated to 50 Concentrated aqueous ammonia is added while monitoring the pH of the solution. At pH=5.0, the mixture is stirred for an additional 10 min.

while making small adjustments to pH 5.0 and the solution is freeze dried to obtain 20.4 gm of a white powder. The partial ammonium salt is then heated to 80 °C in a vacuum oven for conversion to the Glu/Gln co-polymer. Yield: 18.6 gm.

Elemental analysis for N shows this preparation to contain 8% Gln. Titrations to higher pH with ammonia yield higher Gin in the final co-polymer.

Example 8: Synthesis of Glutamic Acid/Proline/Cystine/Tyrosine Heteropolymer (PGlu/Pro/Cys/Tyr) Example 3 is repeated except that 4 separate amino acid NCA's: Glu-NCA 10.71 gm, 62 mmol), Pro-NCA (1.42 gm, 10 mmol), Tyr-NCA (3.54 gm, 17 mmol) and Cys-NCA (1.14 gm, 4 mmol) are dissolved in 86 ml THF prior to polymerization. Glu-NCA is used a synthesized in Example 2. Pro-NCA, Tyr- NCA and Cys-NCA are synthesized as summarized by Blacklock, Hirschmann and Veber (The Peptides 9:39-95, 1987). Cys-NCA is prepared and used as the Bis- Cysteine- NCA (NCA-Cys-S-S-Cys-NCA). Pro-NCA is prepared just prior to use but the remaining NCA's are stable when stored as described in Example 2. Yield: 12.2 gm (76 Example 9: Release of Tryptophan (Trp) from PGlu Trp Blended Tablets A uniform blend of PGlu (19.0 gm) and Trp (1.0 gm) is prepared in a ball mill and 100 mg tablets are prepared as described in Example 13. Tablets are WO 00/52078 PCT/US00/05693 subjected to a standard dissolution test under two pH conditions (pH 1.0 and 6.5) in order to mimic conditions in the stomach and small intestine. In the test, a tablet is placed in a jacketed (37 glass beaker containing 100 ml of the test solution, and stirred at 100 RPM. Samples (0.1 ml) of the solution are taken at 30, 60 and 120 min, diluted 1/10 in water, and the OD measured at a wavelength of 280 nanometers and compared to the control samples containing 5 mg of Trp dissolved in 100 ml of solution. Release of Trp is expressed as of Control (100%).

pH 1.0 pH Trp Released Control) Trp Released Control) Tablet No. 30 min 60 min 120 min 30 min 60 min 120 min 1 0.8 1.1 0.8 98.2 98.1 99.0 2 0.8 0.8 0.7 97.1 98.0 98.2 3 0.7 1.0 0.9 97.5 99.1 98.9 Example 10: Release of Tryptophan (Trp) from PLys Trp Blended Tablets Example 9 is repeated except that tablets were formulated using the helical form of PLys from Example 4.

pH 1.0 pH Trp Released as of Control Trp Released as of Control Tablet No. 30 min 60 min 120 min 30 min 60 min 120 min 1 102.5 101.4 98.4 99.1 98.9 98.9 2 99.1 100.1 100.1 99.0 98.6 98.8 3 99.3 99.2 99.1 98.9 99. 99.3 Example 11: Hydrophobic Inclusion of Tryptophan in PGlu/Phe Tryptophan is included in hydrophobic sites in PGlu/Phe from Example 5 by dissolving 10 gm of the polymer in a solution composed of 50% ethanol and 0.05 M sodium phosphate buffer at pH 7.2.

The solution is bubbled with nitrogen to remove dissolved oxygen.

Tryptophan (1.0 gm) is then added and the pH slowly adjusted to 3.0 by titration WO 00/52078 PCT/US00/05693 with 1.0 N HC1. The precipitate formed is collected by centrifugation and washed by re-suspension in water and the product is freeze dried. Solution of the product in 0.05 M sodium phosphate and measuring the OD at 280 nanometers is used to measure the Trp included in the polymer.

Example 12: Protection of L-DOPA by Hydrophobic Inclusion in PGlu/Phe (PGlu/Phe DOPA) Example 11 is repeated except that L-DOPA is substituted for tryptophan.

Decomposition of DOPA is measured by formation of colored quinone oxidation products, when compared to DOPA alone. DOPA loss is measured by reverse phase HPLC as previously described. Gerlach et al., J. Chromat. 380:379-385, 1986.

Example 13: Tableting for Oral Dosage Forms Oral dosage forms of drugs combined with synthetic polypeptides can be prepared by direct compression of the polypeptide drug combination. Alternatively, the synthetic polypeptide/drug combination can be combined with other excipients to enhance tablet properties, as described for 5 mg hydrocortisone in a 200 mg tablet.

Component mg/Tablet 1. Lys/Phe-Hydrocortisone 35.0 17.50 2. Microcrystalline Cellulose 25.5 12.75 3. Lactose 135.25 67.63 4. Croscarmellose 3.40 1.70 Mg2+ Stearate 0.85 0.42 Total: 200.00 mg 100.00 Procedure: A pre-mix of the Plys/Phe-Hydrocortisone combination and cellulose is blended to uniformity and then blended with the remaining ingredients, except stearate, until uniform. Finally, the stearate is added and blended 5 min.

Tablets are formed by direct compression to a hardness of 16 kg.

WO 00/52078 PCT/US00/05693 Example 14: Blending and Tableting of PGlu Aspirin A uniform blend of equal masses of PGlu and aspirin is prepared in a shell blender and 200 mg tablets containing 100 mg aspirin each are compressed as described in Example 13 to a hardness of 7 kg.

Example 15: Blending and Tableting of Plys/Phe Cortisol Example 11 is repeated except that hydrocortisone (17hydroxycorticosterone) is substituted for Trp and tableted with other excipients as described in Example 13. Hydrocortisone in the tablets is determined by quantitative reverse phase HPLC of solutions containing dissolved tablets as previously described. Waters Corporation, Symmetry Applications Notebook II, August, 1994, p. 19.

Example 16: Stability of Gln in Pglu/Gln Co-Polymer Stability of Gin in the PGlu/Gln co-polymer of Example 7 is measured by the production of free ammonia in 0.2 M phosphate buffer, as described previously (Gilbert et al., J. Biol. Chem. 180:209, 1949). The Glu/Gln co-polymer yields no detectable ammonia in this assay, while the control sample, containing free Gin is almost completely de-amidated.

Example 17: Use of PGlu/Gln in Cell Culture The co-polymer of Example 7 is dissolved as an 0.8% solution (0.8 gm/100 ml) in a standard media, devoid of monomeric glutamine (alpha-MEM, without glutamine) and combined with insulin (5 ug/ul) and transferrin (holo, 5 ptg/pl). The solution is ajusted to pH 7.2 with 1.0 N NaOH and filtered through a 0.2 micron sterilization membrane. This combined media is found to support growth of cultured human amniocytes, through multiple passages, with no addition of monomeric Lglutamine.

-16- WO 00/52078 PCT/US00/05693 Example 18: Treatment of Gin Deficiency in Humans with Oral Dosage of PGlu/Gln The Glu/Gln co-polymer of Example 7 is formed into tablets by direct compression of 125 mg of the co-polymer, as described in Example 13. This oral dose will suffice as an oral preparation to deliver about 10 mg L-glutamine, in order to treat a deficiency of this essential amino acid in humans.

Example 19: PGlu/Pro/Cys/Tyr as a Synthetic Serum Component The heteropolymer product of example 8 is dissolved in phosphate buffered saline (PBS) and adjusted to pH 7.2 with 1.0 N NaOH, prior to sterile filtration.

This sterile solution is intended as a synthetic serum replacement, to supplement serum volume in humans and other mammals.

Example 20: Treatment for Inflammation The product of Example 14 is tableted by direct compression, as in Example 13, to contain about 50 mg of aspirin per tablet. This preparation is intended as an oral treatment for inflammation in mammals, especially humans.

Example 21: Treatment for Primary Adrenal Insufficiency The product of Example 15 is combined with other excipients to formulate an oral dosage for the treatment of adrenal insufficiency or inflammation in mammals, especially humans.

Example 22: Treatment for Parkinson's Disease The product of Example 12 is tableted by direct compression, as in example 13, to contain 50 mg of L-DOPA per tablet, as oral dosage form for the treatment of Parkinsons disease in humans.

-17- P:\OPERUgc37239-00 spe.doc- 15/123 -17A- Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form or suggestion that that prior art forms part of the common general knowledge in Australia.

Claims (35)

1. A method of producing a polypeptide, comprising co-polymerizing a glutamic acid derivative (Glu) and a phenylalanine derivative (Phe), wherein the molar ratio of Glu/Phe is between 3 and 4.

2. A co-polymer polypeptide made by the method of claim 1.

3. A method of producing a polypeptide, comprising co-polymerizing a lysine derivative (Lys) and a phenylalanine derivative (Phe), wherein the molar ratio of Lys/Phe is between 3 and 4.

4. A co-polymer polypeptide made by the method of claim 3. The method of claim 1 or 3, wherein at least one Phe is replaced by a derivative of an amino acid selected from the group consisting of gamma- benzylglutamic acid, tyrosine, 3-Iodo-tyrosine, 3,5-diiodo-tyrosine, glycine, alanine, valine, leucine, isoleucine, and methionine.

6. A method of producing a polypeptide that consists essentially of glutamic acid and glutamine residues, comprising co-polymerization of at least one residue of glutamic acid and at least one residue of glutamine.

7. A co-polymer polypeptide that consists essentially of glutamic acid and glutamine residues.

8. A method of treating glutamine deficiency in mammals comprising oral administration of the co-polymer polypeptide of claim 7.

9. Use of the co-polymer polypeptide of claim 7 as a nutritional source of glutamine in cell culture. P:\OPERUgc\37239-00 spe.doc-15/12/03 -19- Use of the co-polymer polypeptide of claim7 as a serum substituted in cell culture.

11. A method of producing a cystine cross-linked polypeptide that consists essentially of the constituent amino acids Cys, Pro, Glu, and Tyr, comprising copolymerizing a Cys derivative, a Pro derivative, a Glu derivative, and a Tyr derivative.

12. A cystine cross-linked polypeptide that consists essentially of Cys, Pro, Glu, and Tyr residues.

13. Use of the polypeptide of claim 12 in a synthetic serum substitute.

14. A polypeptide of any one of claims 2, 4, 7 or 12, wherein at least one amino acid residue is a D-amino acid.

15. A composition comprising a non-covalently linked drug substance and the polypeptide according to any one of claims 2, 4, 7 or 12.

16. The composition of claim 15, further comprising at least one pharmaceutically acceptable excipient.

17. The composition of claim 15, wherein the drug substance is selected from the group consisting of a nutrient, a hormone, a neurotransmitter, and a metabolic intermediate.

18. The composition of claim 15, wherein the drug substance is capable of partitioning into a hydrophobic domain of the polypeptide.

19. The composition of claim 15, wherein the polypeptide is capable of releasing the oo drug substance in a pH-dependent manner.

20. The composition of claim 19, wherein the polypeptide is capable of releasing the 20. The composition of claim 19, wherein the polypeptide is capable of releasing the P:\OPERUgc\37239-00 spc.doc-15/1203 drug substance in the small intestine.

21. The composition of claim 19, wherein the polypeptide is capable of releasing the drug substance in the stomach.

22. The composition of claim 15, wherein the polypeptide has a free energy of folding between about 3 kcal/mol and about 50 kcal/mol.

23. The composition of claim 15, wherein the diffusion rate of the drug substance from the polypeptide is temperature-sensitive.

24. The composition of claim 15, wherein the drug substance is tryptophan. The composition of claim 15, wherein the polypeptide is the polypeptide of claim 4 and the drug substance is hydrocortisone.

26. A method of treating primary adrenal insufficiency comprising oral administration of the composition of claim 20 27. The composition of claim 14, wherein the polypeptide is the polypeptide of claim 2 or 4 and the drug substance is L-DOPA.

28. A method of treating Parkinson's disease comprising oral administration of the composition of claim 27.

29. The composition of claim 15, wherein the polypeptide is the polypeptide of claim 2 or 4 and the drug substance is aspirin.

30. A method of treating inflammation comprising oral administration of the composition of claim 29. *~oo P:\OPER\gcU7239-00 spc doc- 15/1203 -21

31. A method of tableting, comprising blending a chemical compound with a synthetic polypeptide by direct compression.

32. The method of claim 31, wherein the chemical compound is aspirin and the polypeptide is polymeric glutamic acid.

33. The method of claim 31, wherein the chemical hydrocortisone, and the synthetic polypeptide is a co-polymer of lysine (Lys) and phenylalanine (Phe), wherein the molar ratio of Lys/Phe is between 3 and 4.

34. The method of claim 31, further comprising blending at least one excipient. The method of claim 34, wherein said at least one excipient is selected from the group consisting of a filler, a pH buffer, an anti-oxidant, a disintegrant, a glidant, a lubricant, and a binder.

36. A method of synthesizing glutamic acid N-carboxyanhydride (Glu-NAC), wherein gamma carboxyl protection is not required, comprising maintaining the reaction temperature at 50 0 C until the synthesis reaction is homogenous, and then heating 20 the synthesis reaction to 63 0 C for about 1 hour.

37. The method of claim 36, further comprising purifying Glu-NAC under carbon dioxide.

38. The method of claim 37, further comprising storing the purified Glu-NAC in the cold, under carbon dioxide, and in the dark.

39. A method of polymerizing glutamic acid N-carboxyanhydride (Glu-NAC), comprising initiating polymerization by addition of anhydrous ethyl acetate a containing triethylamine, then warming the reaction to reflux, then cooling the reaction. P:\OPERUgc\37239-0 spe.doc- 15/12/03 -22- The method of claim 39, further comprising purifying the polymer and converting the polymer to helical form.

41. A pharmaceutical composition, comprising poly-L-Lysine in helical form. DATED this 15 th day of December, 2003 NEW RIVER PHARMACEUTICALS INC by its Patent Attorneys DAVIES COLLISON CAVE o oO*